Lewy Body & Parkinson Dementia
Dementia with Lewy Bodies & Parkinson Disease Dementia
What Do You Need to Know?
- DLB core features: fluctuating cognition, recurrent well-formed visual hallucinations, REM sleep behavior disorder (RBD), spontaneous parkinsonism
- 1-year rule: dementia within 1 year of parkinsonism = DLB; dementia ≥1 year after established parkinsonism = PDD — same α-synuclein Lewy body pathology on a spectrum
- Neuroleptic sensitivity: even atypical antipsychotics can cause severe/fatal reactions; if absolutely needed → low-dose quetiapine or clozapine (per 2017 DLB consensus); pimavanserin is sometimes used off-label in DLB but is FDA-approved only for PD psychosis
- Indicative biomarkers: reduced dopamine transporter uptake (DaTscan), abnormal 123I-MIBG cardiac scintigraphy, PSG-confirmed RBD without atonia
- Cognitive profile: attention, executive function, and visuospatial domains disproportionately impaired early; memory relatively preserved (vs. AD)
- Treatment: rivastigmine (strongest evidence among cholinesterase inhibitors); for RBD in DLB/PDD, secure the sleep environment and use a guideline-supported agent — AASM 2023 conditionally recommends immediate-release melatonin, clonazepam, and rivastigmine; IR melatonin is often preferred initially in dementia for safety, with clonazepam reserved (caution: falls, delirium, OSA); cautious carbidopa-levodopa for motor symptoms
- Imaging: relative preservation of medial temporal lobe/hippocampus (vs. AD); occipital hypometabolism on FDG-PET; "cingulate island sign"
🚩 Don’t Miss — Test-Day Priorities
- 4 core clinical features (McKeith 2017): fluctuating cognition, recurrent well-formed visual hallucinations, RBD, spontaneous parkinsonism — ≥2 features = probable DLB (or 1 core + ≥1 indicative biomarker)
- 1-year rule: dementia onset ≤1 yr of parkinsonism = DLB; dementia >1 yr after established parkinsonism = PDD — same underlying α-synuclein Lewy body pathology
- Neuroleptic sensitivity is a hallmark: AVOID haloperidol/typical antipsychotics (severe rigidity, NMS-like reaction, death) — use low-dose quetiapine cautiously; pimavanserin (5HT2A inverse agonist, no D2 block) off-label for psychosis
- Indicative biomarkers (can upgrade certainty): DaTscan with reduced striatal dopamine uptake, PSG-confirmed REM sleep without atonia, reduced 123I-MIBG cardiac uptake
- Supportive biomarkers: relative MTL preservation (vs. AD), posterior hypometabolism with cingulate island sign on FDG-PET, posterior slow-wave EEG with pre-α/θ fluctuations
- DLB vs. AD: visual hallucinations + fluctuations + RBD + DaTscan abnormal (normal in AD) + MTL preserved — AD co-pathology common
- RBD predicts synucleinopathy: ~75–80% of isolated RBD converts to DLB/PD/MSA over 12–14 yr — counsel on future risk
- Treatment pearls: rivastigmine (strongest evidence) > donepezil for cognition; for RBD secondary to DLB/PDD, secure the sleep environment — AASM 2023 conditionally recommends IR melatonin, clonazepam, and rivastigmine; IR melatonin is often preferred initially in dementia for safety (vs. clonazepam, which carries falls / delirium / OSA risk); cautious levodopa (may worsen hallucinations); AVOID anticholinergics, antihistamines, benzodiazepines (as a class)
🔍 Buzzwords & Pathognomonic FindingsClinical · Imaging · Pathology / treatment
Clinical phenotype
- Fluctuating cognition with episodes of staring/unresponsiveness then alert → DLB core feature
- Recurrent well-formed visual hallucinations of people, animals, or children → DLB (often with preserved insight early)
- Dream enactment behavior / RBD preceding dementia by years to decades → prodromal α-synucleinopathy (DLB/PD/MSA)
- Severe extrapyramidal reaction / NMS-like response to haloperidol or typical antipsychotic → neuroleptic sensitivity in DLB
- Capgras syndrome (familiar people are imposters) → DLB-associated delusional misidentification
- Unexplained syncope, recurrent falls, orthostatic hypotension, hyposmia → DLB supportive features
- Marked confusion/worsening with diphenhydramine or anticholinergic → DLB sensitivity
Imaging signs
- Reduced striatal dopamine transporter uptake on DaTscan → DLB (or PD/MSA/PSP) — normal in AD
- Cingulate island sign on FDG-PET (posterior cingulate spared, precuneus/lateral parietal hypometabolic) → DLB
- Occipital hypometabolism on FDG-PET → DLB (distinguishes from AD)
- Relative medial temporal lobe / hippocampal preservation on MRI → DLB (vs. prominent MTL atrophy in AD)
- Reduced 123I-MIBG cardiac scintigraphy (postganglionic sympathetic denervation) → DLB/PD — normal in MSA
- Posterior slow-wave EEG with pre-α/θ fluctuations → DLB supportive biomarker
Pathology / treatment pearls
- Brainstem and cortical α-synuclein Lewy bodies + Lewy neurites → DLB / PDD pathology (concomitant AD pathology common)
- Rivastigmine → strongest evidence cholinesterase inhibitor for DLB cognition and hallucinations
- Pimavanserin (5HT2A inverse agonist, no D2 block) → off-label DLB psychosis; FDA-approved for PD psychosis
- Low-dose quetiapine or clozapine → cautious antipsychotic choice if absolutely needed
- Immediate-release melatonin → AASM 2023 conditionally recommended for RBD; often preferred initially in dementia for safety (vs. clonazepam, which is also guideline-supported but carries falls / delirium / OSA risk)
- Cautious carbidopa-levodopa → parkinsonism in DLB (may worsen hallucinations/psychosis)
- Avoid anticholinergics, antihistamines (diphenhydramine), benzodiazepines → worsen confusion in DLB
- DBS → NOT indicated in DLB/PDD (cognitive impairment is a contraindication)
DLB Diagnostic Criteria (McKeith 2017)
Essential Feature (Required)
- Dementia — progressive cognitive decline of sufficient magnitude to interfere with social/occupational function; prominent or persistent memory impairment may not occur early but usually evident with progression. Required for any DLB diagnosis.
Core Clinical Features
- Fluctuating cognition — pronounced variations in attention and alertness; may mimic delirium; spontaneous "good days and bad days"
- Recurrent visual hallucinations — well-formed, detailed (people, animals, children); often have insight early in course
- REM sleep behavior disorder (RBD) — dream enactment behavior; loss of normal REM atonia; may precede cognitive decline by decades
- Spontaneous parkinsonism — bradykinesia, rigidity, rest tremor; NOT drug-induced; often symmetric or mild early on
Diagnostic Certainty
| Diagnosis | Criteria |
|---|---|
| Probable DLB | ≥2 core features; OR 1 core feature + ≥1 indicative biomarker |
| Possible DLB | 1 core feature without indicative biomarker; OR ≥1 indicative biomarker alone (no core features) |
Indicative Biomarkers
| Biomarker | What It Shows | Board-Relevant Details |
|---|---|---|
| DaTscan (Ioflupane SPECT) | Reduced dopamine transporter uptake in basal ganglia | Abnormal in DLB, PD, MSA, PSP; normal in AD — key differentiator |
| 123I-MIBG cardiac scintigraphy | Reduced cardiac sympathetic innervation | Abnormal in DLB and PD (cardiac sympathetic denervation); normal in AD, MSA |
| PSG-confirmed RBD | REM sleep without atonia on polysomnography | RBD converts to α-synucleinopathy (DLB/PD/MSA): Postuma 2019 multicenter cohort showed ~74% phenoconversion at 12 years; long-term cumulative rates ~75–80% |
Supportive Clinical Features
- Severe neuroleptic sensitivity — exaggerated extrapyramidal response to antipsychotics; can be fatal
- Postural instability and repeated falls
- Syncope or other transient episodes of unresponsiveness
- Severe autonomic dysfunction (orthostatic hypotension, urinary incontinence, constipation)
- Hypersomnia
- Hyposmia (reduced sense of smell)
- Systematized delusions (often paranoid/persecutory)
- Hallucinations in other modalities (auditory, tactile)
- Apathy, anxiety, depression
Supportive Biomarkers
- Relative preservation of medial temporal lobe on CT/MRI (vs. prominent hippocampal atrophy in AD)
- Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity
- Prominent posterior slow-wave activity on EEG with periodic fluctuations in the pre-alpha/theta range
- Insular thinning on MRI
💎 Board Pearl
- Probable DLB requires ≥2 core features OR 1 core + 1 indicative biomarker — biomarkers can "upgrade" a single core feature to probable
- DLB should NOT be diagnosed if parkinsonism is the only core feature and DaTscan is the only biomarker (both reflect same dopaminergic loss)
- RBD is the most specific predictor of future α-synucleinopathy — if present with cognitive decline, DLB is the leading differential
- Supportive biomarkers (MRI MTL preservation, occipital hypometabolism on FDG-PET, EEG posterior slow waves) are consistent with DLB but do NOT by themselves allow a Probable DLB diagnosis — only INDICATIVE biomarkers (DaTscan, MIBG, PSG-confirmed RBD) can upgrade certainty to Probable DLB
DLB vs. PDD vs. AD — The Key Comparisons
The 1-Year Rule
- DLB: dementia develops before or within 1 year of onset of parkinsonism
- PDD: dementia develops ≥1 year after well-established parkinsonism (usually many years into PD course)
- Both are α-synucleinopathies with cortical Lewy bodies — considered the same pathological spectrum
- The 1-year rule is a clinical convenience, not a biological boundary
Master Comparison Table: DLB vs. PDD vs. AD
| Feature | DLB | PDD | AD |
|---|---|---|---|
| Pathology | Cortical Lewy bodies (α-synuclein); often concomitant AD pathology | Cortical Lewy bodies (α-synuclein) | Amyloid plaques + neurofibrillary tangles (tau) |
| Timing | Dementia before or within 1 yr of parkinsonism | Dementia ≥1 yr after established parkinsonism | No parkinsonism at onset |
| Motor features | Spontaneous parkinsonism; often symmetric, less tremor-dominant | Preceded by typical PD motor features (asymmetric rest tremor) | Parkinsonism uncommon; if present, usually late and mild |
| Visual hallucinations | Early, prominent, well-formed | Common, usually later in PD course | Uncommon until late stages |
| Cognitive profile | Attention/executive/visuospatial worst; memory relatively preserved | Similar to DLB: executive/visuospatial | Episodic memory impairment earliest and most prominent |
| Fluctuations | Marked, prominent | Present but less prominent | Absent or minimal |
| RBD | Very common (core feature) | Very common | Uncommon |
| Neuroleptic sensitivity | Severe (hallmark) | Present | Not a typical feature |
| DaTscan | Abnormal | Abnormal | Normal |
| MIBG cardiac | Abnormal (reduced uptake) | Abnormal | Normal |
| MRI | Medial temporal lobe relatively preserved | Variable hippocampal atrophy | Early hippocampal/medial temporal atrophy |
| FDG-PET | Occipital hypometabolism; cingulate island sign | Similar to DLB | Temporoparietal hypometabolism; no cingulate island sign |
| Cholinesterase inhibitors | Effective (rivastigmine preferred) | Effective (rivastigmine FDA-approved) | Effective (donepezil most commonly used) |
| Levodopa response | Variable; less robust than PD | Initial response good (they have PD); may wane | Not applicable |
💎 Board Pearl
- The 1-year rule is the single most tested distinction between DLB and PDD: dementia within 1 year of motor onset = DLB; dementia ≥1 year after = PDD
- DaTscan abnormal + preserved medial temporal lobes + visual hallucinations = classic board-question DLB presentation (vs. AD)
- Concomitant AD pathology (amyloid plaques) is common in DLB and is associated with faster cognitive decline, shorter survival, and fewer/less prominent visual hallucinations and fluctuations (more AD-like memory-predominant profile)
Pathology
Lewy Body Formation
- Lewy bodies: intracytoplasmic, eosinophilic, spherical inclusions with a dense hyaline core and pale halo
- Composed primarily of misfolded α-synuclein + ubiquitin, neurofilament
- Lewy neurites: α-synuclein-positive dystrophic neurites; more numerous than Lewy bodies and likely more pathologically significant
- Brainstem Lewy bodies (substantia nigra, locus coeruleus) → motor parkinsonism
- Cortical Lewy bodies (limbic → neocortical) → cognitive impairment, hallucinations
Distribution Patterns
| Pattern | Distribution | Clinical Correlate |
|---|---|---|
| Brainstem-predominant | Substantia nigra, locus coeruleus, dorsal raphe, dorsal motor nucleus of vagus | Classical PD without dementia |
| Limbic (transitional) | Brainstem + amygdala, cingulate gyrus, transentorhinal cortex | PD with mild cognitive impairment; early DLB |
| Neocortical (diffuse) | Brainstem + limbic + frontal, temporal, parietal cortices | DLB or PDD with prominent dementia |
Concomitant AD Pathology in DLB
- 50–80% of DLB cases have concurrent AD pathology (amyloid plaques ± neurofibrillary tangles); ~30–50% meet criteria for intermediate-to-high AD neuropathologic change
- Higher amyloid burden in DLB correlates with: faster cognitive decline, shorter survival, fewer/less prominent visual hallucinations and fluctuations, and a more AD-like (memory-predominant) cognitive profile
- Pure Lewy body pathology (without AD copathology) → more classic DLB phenotype with prominent fluctuations and visual hallucinations
- Mixed AD + Lewy body pathology is one of the most common neuropathological findings at autopsy in elderly with dementia
💎 Board Pearl
- α-synuclein is the protein that forms Lewy bodies; tau forms neurofibrillary tangles (AD, PSP, CBD); TDP-43 is the hallmark of FTLD and ALS
- Braak PD staging tracks α-synuclein spread: olfactory bulb/dorsal motor nucleus → locus coeruleus → substantia nigra → mesocortex → neocortex
- Mixed AD + Lewy body pathology is the most common autopsy finding in patients clinically diagnosed with "AD" who also had visual hallucinations
Cognitive Profile
Cognitive Domains in DLB/PDD vs. AD
| Domain | DLB / PDD | AD |
|---|---|---|
| Attention | Severely impaired early; marked fluctuations | Relatively preserved early |
| Executive function | Disproportionately impaired (planning, set-shifting, judgment) | Impaired but less prominent than memory |
| Visuospatial | Severely impaired (clock drawing, figure copy, visual construction) | Impaired later; less severe |
| Episodic memory | Relatively preserved early; retrieval deficit (improves with cues) | Earliest and most impaired; encoding deficit (does NOT improve with cues) |
| Language | Generally preserved early | Word-finding difficulty early; semantic errors |
| Processing speed | Markedly slowed | Slowed but less pronounced |
Fluctuating Cognition
- Hallmark of DLB; described as spontaneous alterations in cognition, attention, and arousal
- May manifest as: staring spells, episodes of incoherent speech, excessive daytime somnolence alternating with lucid intervals
- Can mimic delirium — always consider DLB when an elderly patient has "delirium" without clear precipitant
- Clinician Assessment of Fluctuation (CAF) and One Day Fluctuation Assessment Scale — validated tools
- Fluctuations are more prominent in DLB than PDD
Clinical Pearl
- A patient with "delirium" that waxes and wanes over weeks without identifiable cause + well-formed visual hallucinations should raise suspicion for DLB, not just a metabolic workup
- DLB patients perform worse on clock drawing and figure copy than AD patients at the same stage of overall dementia severity — visuospatial testing is a key differentiator
Visual Hallucinations
Characteristics in DLB
- Well-formed and detailed — people (often children or strangers), animals, objects
- Typically visual; may be accompanied by auditory hallucinations but visual predominate
- Often occur in low-light conditions or at transitions between wakefulness and sleep
- Patient may have full or partial insight early in course (knows hallucinations are not real)
- Recurrent and stereotyped (similar content over time)
- Associated with cholinergic deficit in visual cortex and reduced occipital metabolism
Differential Diagnosis of Visual Hallucinations
| Condition | Hallucination Type | Distinguishing Features |
|---|---|---|
| DLB | Well-formed people/animals; recurrent | Associated parkinsonism, fluctuations, RBD; insight often preserved early |
| Charles Bonnet syndrome | Well-formed, complex visual imagery | Occurs with visual loss (macular degeneration, cataracts); no cognitive decline; full insight; no parkinsonism |
| Delirium | Poorly formed, often frightening | Acute onset; identifiable precipitant (infection, metabolic, medication); resolves with treatment |
| PD psychosis | Well-formed; often passage/presence hallucinations early | Occurs in context of long-standing PD; often medication-related (dopamine agonists > levodopa) |
| Peduncular hallucinosis | Vivid, well-formed, often at night | Midbrain/thalamic lesion; often have insight; associated with sleep disturbance |
| Epileptic (occipital seizures) | Elementary visual phenomena (flashes, colors); rarely formed | Brief, stereotyped, may have associated eye deviation |
💎 Board Pearl
- Well-formed visual hallucinations in an elderly patient with fluctuating cognition = DLB until proven otherwise
- Charles Bonnet syndrome is the main mimic — distinguished by visual loss, intact cognition, and absence of parkinsonism/RBD
- In PD, hallucinations often begin as minor phenomena (passage hallucinations — something moving in peripheral vision; presence hallucinations — feeling someone is nearby) before progressing to well-formed visual hallucinations
Neuroimaging
Structural MRI
- Relative preservation of medial temporal lobe and hippocampus — key distinction from AD
- Global cortical atrophy may be present but less specific
- Posterior cortical atrophy (parieto-occipital) may be seen
- MRI mainly useful to exclude other causes and to demonstrate absence of typical AD pattern
Functional and Molecular Imaging
| Modality | DLB Finding | AD Finding | Clinical Utility |
|---|---|---|---|
| FDG-PET | Occipital hypometabolism; relative preservation of posterior cingulate ("cingulate island sign") | Temporoparietal hypometabolism; posterior cingulate affected early | Cingulate island sign helps distinguish DLB from AD |
| DaTscan (SPECT) | Reduced striatal dopamine transporter uptake | Normal | Indicative biomarker for DLB; differentiates from AD |
| MIBG cardiac | Reduced heart-to-mediastinum ratio | Normal | Indicative biomarker; reflects cardiac sympathetic denervation |
| Amyloid PET | Positive in ~50% (concomitant AD pathology) | Positive (>90%) | Does NOT differentiate DLB from AD (both can be positive) |
| Perfusion SPECT | Reduced occipital perfusion | Reduced temporoparietal perfusion | Supportive biomarker for DLB |
💎 Board Pearl
- Cingulate island sign: relative preservation of posterior cingulate metabolism on FDG-PET in DLB (vs. early posterior cingulate hypometabolism in AD) — high specificity for Lewy body pathology
- DaTscan differentiates DLB from AD (abnormal in DLB, normal in AD) but does NOT distinguish DLB from MSA, PSP, or CBD
- Amyloid PET is NOT useful for DLB vs. AD differentiation — ~50% of DLB patients are amyloid-positive
Neuroleptic Sensitivity
Why It Matters
- Up to 50% of DLB patients have severe neuroleptic sensitivity reactions
- Reactions include: severe worsening of parkinsonism, impaired consciousness, rigidity, autonomic instability
- Can be fatal — resembles neuroleptic malignant syndrome (NMS)
- Mechanism: severe loss of nigrostriatal dopaminergic neurons + post-synaptic D2 receptor blockade → catastrophic dopamine depletion
- Occurs with typical antipsychotics (haloperidol, chlorpromazine) AND can occur with atypical antipsychotics (risperidone, olanzapine)
Management of Psychosis in DLB
Step 1: Non-pharmacologic and Medication Review
- Reduce or eliminate anticholinergics, benzodiazepines, dopamine agonists (taper before levodopa)
- Environmental modifications (adequate lighting, reduce sensory overload)
- Optimize cholinesterase inhibitor dose (may reduce hallucinations)
Step 2: If Antipsychotic Absolutely Needed
| Agent | Notes | Board Relevance |
|---|---|---|
| Pimavanserin | Selective 5-HT2A inverse agonist; no dopamine receptor blockade | FDA-approved for PD psychosis; does NOT worsen motor function; onset of effect over 2–6 weeks; QTc prolongation risk; FDA boxed warning for increased mortality in elderly patients with dementia-related psychosis (class warning for all antipsychotics) |
| Quetiapine | Atypical antipsychotic with low D2 affinity | Lowest risk of worsening parkinsonism among atypicals; commonly used off-label; evidence base is modest |
| Clozapine | Atypical antipsychotic; minimal D2 blockade | Effective but requires absolute neutrophil count monitoring (agranulocytosis risk ~0.8% (<1%)); rarely used due to monitoring burden |
💎 Board Pearl
- NEVER give haloperidol to a patient with DLB — this is a classic board question; can cause irreversible parkinsonism or death
- Risperidone and olanzapine are also dangerous in DLB despite being "atypical" — they have significant D2 blockade
- Pimavanserin is the only FDA-approved drug for PD psychosis — works via 5-HT2A inverse agonism without dopamine blockade
- Cholinesterase inhibitors (rivastigmine) can improve hallucinations in DLB — always optimize before adding an antipsychotic
Treatment
Cognitive Symptoms
| Agent | Class | Evidence & Notes |
|---|---|---|
| Rivastigmine | Cholinesterase inhibitor (AChE + BuChE) | Strongest evidence in DLB/PDD; FDA-approved for PDD ONLY — use in DLB is off-label but supported by strong evidence (McKeith 2000 RCT); improves cognition, behavioral symptoms, and hallucinations; patch formulation reduces GI side effects |
| Donepezil | Cholinesterase inhibitor (AChE) | Also effective; Phase III Japanese RCTs (Mori et al. 2012, 2015) led to donepezil approval for DLB in Japan; not FDA-approved for DLB in the US; may worsen parkinsonism in some patients |
| Galantamine | Cholinesterase inhibitor + nicotinic allosteric modulator | Less studied in DLB; may have benefit |
| Memantine | NMDA receptor antagonist | Modest benefit; may be added to cholinesterase inhibitor; generally well-tolerated |
Motor Symptoms
- Carbidopa-levodopa: first-line for motor parkinsonism in DLB; start low, titrate slowly
- Response is often less robust than in idiopathic PD
- Risk of worsening hallucinations and psychosis — balance motor benefit vs. psychiatric side effects
- Avoid dopamine agonists (pramipexole, ropinirole) — higher risk of hallucinations, impulse control disorders, and confusion
- Avoid anticholinergics (trihexyphenidyl, benztropine) — worsen cognition and hallucinations
- DBS (STN or GPi) is generally contraindicated in PDD/DLB — established dementia is an exclusion criterion in most DBS programs due to risk of postoperative cognitive worsening
- Levodopa response in PDD: motor response usually preserved in PDD; may develop motor fluctuations/dyskinesias as in PD
RBD Management
| Treatment | Details |
|---|---|
| Immediate-release melatonin (3–12 mg at bedtime) | AASM 2023 conditional recommendation; often preferred initially in dementia for safety; may restore REM atonia; fewer side effects; may need higher doses |
| Clonazepam (0.25–1 mg at bedtime) | AASM 2023 conditional recommendation; reduces injurious behaviors; risk of sedation, falls, worsened OSA, delirium — use cautiously in elderly / patients with cognitive impairment |
| Rivastigmine | AASM 2023 conditional recommendation for secondary RBD in α-synucleinopathies (already first-line for DLB/PDD cognition; treats both) |
| Environmental safety | Remove sharp objects from bedside; pad bed rails; consider floor mattress; bed partner safety |
Other Symptoms
- Autonomic dysfunction: orthostatic hypotension (fludrocortisone, midodrine, droxidopa); constipation (fiber, osmotic laxatives); urinary symptoms (avoid anticholinergics)
- Depression: SSRIs preferred (sertraline, citalopram); avoid tricyclics (anticholinergic burden)
- Excessive daytime somnolence: modafinil may help; optimize nighttime sleep
Clinical Pearl
- Rivastigmine is the only cholinesterase inhibitor with FDA approval for PDD; it also has the strongest evidence base in DLB
- DLB has a greater cholinergic deficit than AD (more basal forebrain loss) — this explains the often dramatic response to cholinesterase inhibitors
- Always add carbidopa-levodopa slowly and at the lowest effective dose — if hallucinations worsen, reduce levodopa and optimize rivastigmine first
RBD as a Prodromal Marker
Key Concepts
- RBD (REM sleep behavior disorder): loss of normal REM atonia → dream enactment (punching, kicking, shouting, falling out of bed)
- Diagnosed by polysomnography showing REM sleep without atonia (RSWA) + history of dream enactment
- Idiopathic/isolated RBD (iRBD) is the strongest known prodromal marker for α-synucleinopathy
Phenoconversion Rates
| Timeframe | Conversion Rate to α-Synucleinopathy |
|---|---|
| 5 years | ~33% |
| 12 years (Postuma 2019) | ~74% |
| Long-term cumulative | ~75–80% |
- Phenoconversion type (Postuma 2019 Brain 142:744): PD ~43%, DLB ~25–35%, MSA <5%
- Conversion to DLB is more common when RBD is accompanied by early cognitive changes
💎 Board Pearl
- Isolated RBD converts to an α-synucleinopathy in ~74% at 12 years (Postuma 2019), with long-term cumulative rates ~75–80% — it is the most specific prodromal biomarker
- If a question describes an elderly man who "acts out his dreams" and injures his bed partner, then years later develops visual hallucinations and parkinsonism → DLB
- Secondary RBD causes to exclude: medications (SSRIs, SNRIs, TCAs, beta-blockers), narcolepsy, brainstem lesions
Autonomic Dysfunction
Key Features
- Autonomic dysfunction is a supportive feature of DLB and very common in both DLB and PDD
- Reflects Lewy body deposition in autonomic ganglia, intermediolateral cell column, and brainstem autonomic nuclei
Autonomic Manifestations
| System | Manifestation | Management |
|---|---|---|
| Cardiovascular | Orthostatic hypotension, postprandial hypotension, supine hypertension | Midodrine, droxidopa, fludrocortisone; compression stockings; salt supplementation; elevate head of bed |
| Gastrointestinal | Constipation (often earliest autonomic symptom), gastroparesis, dysphagia | Fiber, polyethylene glycol; avoid anticholinergics |
| Urogenital | Urinary urgency/frequency, nocturia, erectile dysfunction | Mirabegron (beta-3 agonist) preferred over antimuscarinics; avoid oxybutynin (crosses BBB) |
| Thermoregulatory | Anhidrosis, heat intolerance | Environmental modifications |
💎 Board Pearl
- Early severe autonomic failure (≤5 years of parkinsonism onset) is a red flag for MSA, not PD — but moderate autonomic dysfunction is common and expected in DLB/PDD
- Droxidopa is FDA-approved for neurogenic orthostatic hypotension in PD/DLB/MSA — it is a norepinephrine prodrug
- MIBG cardiac scintigraphy is abnormal in DLB/PD but normal in MSA — this distinction can help differentiate on boards
Prognosis & Distinguishing Features Summary
Prognosis
- DLB median survival from diagnosis: 5–8 years (shorter than AD)
- DLB with concomitant AD pathology has the worst prognosis
- PDD develops in ~50% of PD patients by 10 years and ~80% by 20 years of PD duration (Hely 2008 Sydney; Aarsland 2003 CamPaIGN)
- Rate of cognitive decline in DLB is faster than AD in most studies
- Visual hallucinations, fluctuations, and neuroleptic sensitivity may improve with cholinesterase inhibitors but parkinsonism is progressive
Quick-Hit Board Review Table
| Board Question Clue | Think… |
|---|---|
| Visual hallucinations + fluctuating cognition + parkinsonism | DLB |
| Long-standing PD patient develops dementia years later | PDD |
| Worsened parkinsonism after haloperidol | DLB with neuroleptic sensitivity |
| Preserved hippocampi + occipital hypometabolism on FDG-PET | DLB (cingulate island sign) |
| Abnormal DaTscan + normal in "AD" workup | DLB, not AD |
| Elderly man acting out dreams + later develops dementia | RBD → DLB |
| Dementia + parkinsonism + reduced MIBG uptake | DLB (cardiac sympathetic denervation) |
| Rivastigmine improves both cognition and hallucinations | DLB (cholinergic deficit) |
| Well-formed visual hallucinations + intact vision + no PD | Consider DLB (vs. Charles Bonnet if visual loss present) |
| Early severe orthostatic hypotension + poor levodopa response | MSA (not DLB) |
💎 Board Pearl
- DLB is the second most common neurodegenerative dementia after AD, accounting for 15–25% of dementia at autopsy
- DLB is frequently misdiagnosed as AD — always ask about visual hallucinations, fluctuations, RBD, and parkinsonism
- The combination of abnormal DaTscan + preserved medial temporal lobes + visual hallucinations + RBD is virtually diagnostic of DLB on boards
References
- McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
- Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-1707.
- Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157-169.
- Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744-759.
- Graff-Radford J, Lesnick TG, Boeve BF, et al. Predicting survival in dementia with Lewy bodies with hippocampal volumetry. Mov Disord. 2016;31(7):989-994.
- Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540.
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509-2518.
- Fujishiro H, Ferman TJ, Boeve BF, et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies. J Neuropathol Exp Neurol. 2008;67(7):649-656.
- Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
- Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683-1697.
Continue reading — sign in
The full note has more clinical pearls, tables, and board-focused tips. Free account, no fee.